Evidence map›Paper›PMID 37179654›Full record

ArticleRheumatology advances in practice2023

Impact of the COVID-19 pandemic on patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative (OBRI).

Matthew Wong-Pack, Elliot Hepworth, Mohammad Movahedi, Bindee Kuriya, Janet Pope, Edward Keystone, Carter Thorne, Vandana Ahluwalia, Angela Cesta, Carol Mously and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology advances in practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Matthew Wong-PackDivision of Rheumatology, University of Toronto, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-8240-2665
Elliot HepworthDivision of Rheumatology, University of Ottawa, Ottawa, ON, Canada.
Mohammad MovahediToronto General Research Institute, University Health Network, Toronto, ON, Canada.
Bindee KuriyaDivision of Rheumatology, University of Toronto, Toronto, ON, Canada.
Janet PopeDivision of Rheumatology, University of Western Ontario, London, ON, Canada.ORCID https://orcid.org/0000-0003-1479-5302
Edward KeystoneDepartment of Medicine, University of Toronto, Toronto, ON, Canada.ORCID https://orcid.org/0000-0001-6606-0071
Carter ThorneCentre of Arthritis Excellence, Newmarket, ON, Canada.
Vandana AhluwaliaDivision of Rheumatology, William Osler Health System, Brampton, ON, Canada.
Angela CestaToronto General Research Institute, University Health Network, Toronto, ON, Canada.
Carol MouslyToronto General Research Institute, University Health Network, Toronto, ON, Canada.
Claire BombardierDivision of Rheumatology, University of Toronto, Toronto, ON, Canada.
Arthur LauDivision of Rheumatology, McMaster University, Hamilton, ON, Canada.
Sibel Zehra AydinDivision of Rheumatology, University of Ottawa, Ottawa, ON, Canada.
University of Toronto · CAUniversity Health Network · CAUniversity of Ottawa · CAMcMaster University · CASouthlake Regional Health Center · CAWestern University · CAWilliam Osler Health System · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The coronavirus disease 2019 (COVID-19) pandemic created challenges for patients with RA. We examined the potential impact of the pandemic on patient-reported outcomes (PROs), disease activity and medication profiles, comparing the periods pre-pandemic and during the pandemic. Methods: Patients enrolled in the Ontario Best Practices Research Initiative were included if they had at least one visit to a physician or study interviewer within 12 months before and after the start of pandemic-related closures in Ontario (15 March 2020). Baseline characteristics, disease activity, PROs [i.e. health assessment questionnaire disability index, RA disease activity index (RADAI), European quality of life five-dimension questionnaire], medication use and changes were included. Student's paired two-sample Results: The sample for analysis consisted of 1508 patients, with a mean (s.d.) age of 62.7 (12.5) years, and 79% were female. Despite decreases in the number of in-person visits during the pandemic, there was no significant negative impact on disease activity or PRO scores. The DASs in both periods remained low, with either no clinically significant differences or slight improvement. Scores for mental, social and physical health were either stable or improved. There were statistically significant decreases in conventional synthetic DMARD use ( Conclusion: In this cohort, disease activity and PROs of RA patients remained stable during the COVID-19 pandemic. The longer-term outcomes of the pandemic warrant investigation.

Indexed as

coronavirusCOVID-19disease activitymedication adherencepatient-reported outcomeRArheumatic diseases

Identifiers

PMID37179654
PMCPMC10172034
OpenAlexW4367059562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.